On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.’s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults.Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S.Yuvezzi is expected to be broadly commercially available in the U.S. in the second q ...

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “Make it VIZZable” campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops. VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq ...

Financial Results - LENZ Therapeutics, Inc. reported preliminary, unaudited financial results for Q4 2025, ending December 31, 2025[4] - The financial results are subject to change upon completion of the company's accounting and annual audit procedures[4] - A press release detailing these results was issued on January 7, 2026[4] - The financial statements and additional disclosures are necessary for a complete understanding of the company's financial position[4] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]

Core Insights - LENZ Therapeutics launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025, marking it as the first and only aceclidine-based eye drop for presbyopia treatment, with broad availability by mid-November 2025 [1][5] - The company reported approximately $1.6 million in net product revenue and over 20,000 prescriptions filled in Q4 2025, indicating strong initial market acceptance [1][7] - More than 6,500 unique eye care professionals (ECPs) prescribed VIZZ, with over 55% prescribing it multiple times, reflecting early confidence in the product [2][7] Commercial Highlights - The first commercial sale of VIZZ occurred in October 2025, with full multi-channel access established through e-pharmacy and nearly all retail pharmacies by mid-November 2025 [7] - The rapid uptake by prescribing ECPs is notable, with over 6,500 unique ECPs participating in the prescription process [7] Corporate Updates - In January 2026, LENZ announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East, which includes upfront, regulatory, and commercial milestone payments, along with a significant revenue share [4] - This partnership represents the fourth commercialization agreement for VIZZ outside the United States, indicating the company's strategy to expand its international presence [4] Product Information - VIZZ is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [9] - The product is indicated for age-related blurry near vision (presbyopia) in adults, a condition affecting approximately 1.8 billion people globally [5][10]

Core Viewpoint - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus to register and commercialize VIZZ for the treatment of presbyopia in the Middle East region, marking a significant expansion of its commercial partnerships outside the United States [1] Group 1: Agreement Details - The agreement allows Lunatus to retain exclusive commercialization rights for VIZZ in several Middle Eastern countries, including the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq [1] - LENZ Therapeutics will receive upfront, regulatory, and commercial milestone payments, along with a significant share of revenue generated in the region through a pre-determined minimum product supply price [1] Group 2: Product Information - VIZZ is the first and only FDA-approved aceclidine-based eye drop specifically for the treatment of presbyopia, highlighting its unique position in the market [1] - The commercial launch of VIZZ in the United States is gaining momentum, which supports the strategic expansion into international markets [1] Group 3: Company Strategy - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, demonstrating the company's commitment to expanding global access to this presbyopia therapy [1]

Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving LENZ Therapeutics, Inc. following a significant drop in its stock price due to adverse event reports related to its product [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of LENZ Therapeutics, Inc. and is looking into whether the company and its officers or directors have engaged in fraudulent activities [1]. - The investigation was prompted by a report of a retinal tear associated with LENZ's VIZZ eye drop, which was recorded in the FDA's adverse event reporting systems [3]. Group 2: Stock Price Impact - Following the adverse event report on December 12, 2025, LENZ's stock price decreased by $6.36 per share, representing a decline of 25.96%, closing at $18.14 per share on that date [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Company Overview - LENZ Therapeutics, Inc. experienced a significant decline in share price, falling approximately 25% following reports of an "adverse event" related to its leading drug, VIZZ [1] - The decline in shares has continued, with the stock now down around 30% from its previous levels [1] Market Reaction - The market's reaction to the adverse event indicates heightened investor concern regarding the safety and efficacy of VIZZ, which could impact future sales and the company's overall valuation [1]

Core Insights - Lexston Mining Corporation has appointed Buddy Doyle to its newly established Advisory Board, bringing 40 years of experience in mineral exploration [1][4] - Mr. Doyle has a notable history with Rio Tinto PLC, where he served as Exploration Vice President and was involved in significant discoveries such as the Minifie gold deposits and Diavik diamond deposits [2][3] - The company has granted incentive stock options to directors, officers, and consultants to purchase up to 400,000 common shares at a price of $0.115 per share, exercisable for five years [4] Company Overview - Lexston Mining Corporation is a Canadian mineral exploration company focused on acquiring and developing mineral projects to enhance stakeholder value, with current projects located in British Columbia and Nevada [5] - The company trades on the OTCQB Venture Market, which serves early-stage and developing companies, ensuring compliance with reporting and management certification processes [6]

Core Insights - Nevis Brands Inc. has announced significant corporate updates, including product launches and financial agreements, positioning itself for growth in the cannabis beverage market [1][2][3]. Product Launches - The company has relaunched its Major(™) beverages in Arizona, including Major 100mg Fruit Punch, Blackberry Lemonade, and Blueberry, which are now available in multiple dispensaries across the state [1]. - Nevis Brands has secured a purchase agreement for its Happy Apple(™) hemp-derived THC beverages in Ohio, enhancing the brand's presence in a growing market [2]. Financial Developments - Nevis has reached an agreement with SoRSE Technology to make an additional payment of $75,000 towards the remaining $100,000 principal of a note, with plans to pay the remaining $25,000 plus estimated $55,000 in interest by June 2026 [3][4]. - The company aims to complete the payment of the note and allocate additional cash towards expanding its product portfolio in 2026 [4]. Company Overview - Nevis Brands Inc. is focused on building a portfolio of iconic recreational cannabis brands and operates in regulated dispensary markets through strategic partnerships and licensed production facilities [5]. - The company also sells hemp-derived THC products through its website and select distributors [5].